The effect of medroxyprogesterone acetate on conjugated equine estrogen-induced changes in coagulation parameters in postmenopausal women

Journal of Women's Health

Volumn 5, Issue 2, 1996, Pages 121-128

  De Souza, Mary Jane ^a   Nulsen, John C ^b   Sequenzia, Lisa C ^a   Bona, Robert D ^b   Walker, Frederick J ^b   Luciano, Anthony A ^a  

^a NEW BRITAIN GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLASMINOGEN; PROTEIN S;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYSIS; HORMONE SUBSTITUTION; HUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 0029969504     PISSN: 10597115     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.1996.5.121     Document Type: Article

References (35)

1. Stolley PD, Tonascia JA, Tockman MS, Starwell PR, Rutledge AH, Jacobs MP. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975; 102:197.
2. Bottiger LE, Boman IG, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: Effects of lowering oestrogen content. Lancet 1980;1:1097.
3. Stubblefield PG. The effects on hemostasis of oral contraceptives containing desogestril. Am J Obstet Gynecol 1993;168:1047.
4. Daly L, Bonnar J. Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets. Am J Obstet Gynecol 1990;163:430.
5. Notelovitz M, Kitchens CS, Khan FY. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptive: A controlled comparative 12 month clinical trial. Am J Obstet Gynecol 1992;167:1255.
6. Hulsvold IA, Hospers JEH, Meijer JCM, Starkenburg AE, Erich WBM, Bouma BN. Oral contraceptives reduce total protein S but no free protein S. Thromb Res 1987;45:109.
7. Gilabert J, Fernandez HA, Espana F, Aznar J, Estelles A. Physiological coagulation inhibitors (protein C, protein S and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988;49:319.
8. Paganini-Hill R, Rose RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: A prospective study. Br Med J (Clin Res) 1988;297:519.
9. Ross PK, Pike MC, Mack TM, Henderson BE. Oestrogen replacement therapy and cardiovascular disease. In: Drife JO, Studd JW, eds. HRT and osteoporosis. London: Springer-Verlag, 1990:209.
10. Lowe GDO, Greer IA, Cooke TG, et al. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992;305:567.
11. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069.
12. Stampher MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;203:1044.
13. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102.
14. Lobo RA. Estrogen and cardiovascular disease. Ann NY Acad Sci 1990;592:286.
15. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196.
16. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994;84:987.
17. Walker FJ. The regulation of activated protein C by a new protein: A possible function for bovine protein S. J Biol Chem 1980;255:5521.
18. Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: Evidence for a specific binding of protein S to factor VIII. Blood 1995;86(3):1062.
19. Dahlback B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci USA 1981;78:2512.
20. Edson JU, Vogt JM, Huesman DA. Laboratory diagnosis of inherited protein S deficiency. Am J Clin Pathol 1990;94:176.
21. Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986;68:881.
22. Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986;67:504.
23. Walker FJ. Protein S and thrombotic disease. Proc Soc Exp Biol Med 1992;200:285.
24. Meilahn EN, Kuller LH, Matthews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992;2:445.
25. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: Sex differences and effects of the menopause. Br J Haematol 1990;74:77.
26. Notelovitz M, Kitchens CS, Rappaport V, Coone L, Dougherty M. Menopausal status associated with increased inhibition of blood coagulation. Am J Obstet Gynecol 1981;141:149.
27. Notelovitz M, Kitchens C, Ware M, Hirschberg K, Coone L. Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet Gynecol 1983;62:596.
28. The PEPI Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199.
29. Scarabin PY, Bonithon-Kopp C, Bara L, et al. Factor VII activation and menopausal status. Thromb Res 1990;57:227.
30. Caine YB, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68:392.
31. Gordon EM, Williams SR, Frenchek B, Mazur CA, Speroff L. Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII. J Lab Clin Med 1988;111:52.
32. Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Della Volpe A, Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res 1991;62:1.
33. Nachtigall LE, Nachtigall LB. Estrogen issues in relation to cardiovascular disease. J Am Med Women's Assoc 1995;50:7.
34. Sacco RL, Owen J, Mohr JP, Tatemichi TK, Grossman BA. Free protein S deficiency - A possible association with cerebrovascular occlusion. Stroke 1989;20:1657.
35. Psaty BM, Heckbert S, Atkins D, et al. A review of the association of the estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med 1993;153:1421.